The therapy is also approved for treating advanced gastric cancer and relapsed or metastatic cervical cancer after ...

Satri-cel, a CLDN18.2-targeted CAR T-cell therapy, nearly doubles progression-free survival in patients with previously ...

For the first time, a medicine aimed directly at the HER2 protein improved overall survival after gastric cancer progressed ...

Researchers at ASCO's annual meeting also discussed the importance of repeat biopsies to assess HER2 status after first-line ...

In the United States, approximately 55% of resected gallbladder cancer (GBC) patients undergo oncologic surgery without ...

Data shows adding durvalumab (Imfinzi) to the standard chemotherapy combination known as FLOT before and after surgery kept ...

Phase 3 trial shows trastuzumab deruxtecan extends survival by over three months in advanced HER2-positive gastric cancer and ...

A clinical trial using engineered immune cells to hunt cancer cells has reported impressive results for solid tumours, a type ...

AstraZeneca’s immunotherapy Imfinzi has proven it can help certain patients with early-stage stomach cancer, according to ...

Patients with newly diagnosed gastric or gastroesophageal junction (GEJ) cancer who received the PD-L1 inhibitor durvalumab ...

An innovative treatment that reprogrammes immune cells to recognise and kill cancer has been shown to be effective on patients with certain tumours in a pioneering trial. CAR T-cell therapy is usually ...

AstraZeneca and Daiichi Sankyo’s drug extended survival by 30% compared to a widely used regimen, further establishing its ...